Skip to main content

Table 1 Clinico-pathological characteristics, treatment received, and ERα-36 expression in the patient cohort tested (160 patients)

From: ERα-36 regulates progesterone receptor activity in breast cancer

CharacteristicNumberPercent
Age group (years)< 505131.9
> 5010968.1
Menopausal statusPre5735.6
Post10374.4
Tumor size (cm)< 26842.5
> 29257.5
Axillary LN metastasisNo7647.5
Yes8452.5
SBR gradeI2616.3
II7144.4
III6339.4
ERα-66 statusNegative148.8
Positive14590.6
Missing1 
PR statusNegative4025.3
Positive11874.7
Missing2 
HER2 statusNegative12984.9
Overexpressed2315.1
Missing8 
Breast cancer subtypeLuminal14291.6
Basal106.5
HER2 driven31.9
Missing5 
Adjuvant Hormonal treatmentNo2716.9
Yes13383.1
Adjuvant (or neoadj) chemotherapyNo5936.9
Yes10163.1
ERα-36Low9559.4
High6540.6